Carbohydrates Under Target for Type 1 Diabetes Management
Study Details
Study Description
Brief Summary
Recently, there has been an increased interest in limiting carbohydrates (CHO) intakes for improving long-term health. Low CHO (<30% energy from CHO) and very low CHO high fat (VLCHF; 10% CHO, 75% Lipid) diets are being advocated among people living with diabetes given their almost immediate favorable impact on post-prandial blood glucose levels and on hemoglobin A1c that have been reported by users. Adoption of these diets are met with reluctance by healthcare professionals due to the lack of information on their safety. Concerns include the impact on hypoglycemia frequency and glucagon response to hypoglycemia, diabetic ketoacidosis, lipid profile, liver function insulin dose adjustments when adopting them in the context of type 1 diabetes (T1D). Through a series of interviews, people with diabetes following a VLCHF reported that the lack of support from HCPs often leads to hiding the fact that they have adopted a VLCHF diet. This is an important source of concern that can lead to additional safety issues.
The goal is to fill an important knowledge gap about the effectiveness, benefits and risks of low CHO and VLCHF diets for people with T1D. The primary objective is to compare the percentage of TIR of adults with T1D following a low-CHO diet or a VLCHF diet versus a control diet for 12 weeks. The secondary objectives are (1) to evaluate efficacy of glucagon in correcting hypoglycemia in the context of restricted carbohydrates intakes; (2) to evaluate changes in HbA1c at 12 weeks and glucose fluctuations and % of time in hypoglycemia at 6 weeks and 12 weeks of control diet, low-CHO diet or VLCHF diet; (3) to compare key cardiometabolic risk factors (body composition, blood lipids, blood pressure and liver inflammatory markers and function) at 6 weeks and 12 weeks of control diet, low-CHO diet or VLCHF diet; (4) to evaluate the effect of restrictive CHO diets (low-CHO and VLCHF) on the composition of the intestinal microbiota (optional).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: VLCHF (Very Low CHO High Fat) Diet 10% of energy from CHO, 15% proteins, and 75% lipids |
Other: Insulin treatment optimization with participant's usual diet
Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
Device: Abbott's FreeStyle Libre
During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
Other: Three-day food journal
Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
Other: Medical visit
During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
Other: Blood pressure measurements
Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
Other: Anthropometric parameters measurements
Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
Other: Indirect calorimetry test
Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
Other: Well-being questionnaire
Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
Other: Diet appreciation questionnaire
Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
Device: Pedometer (PiezoRxD)
Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
Other: Hepatic imaging (MRI)
Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
Other: Glucagon efficiency test
The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
Other: Body composition : Dual Energy X-ray absorptiometry (DEXA)
Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
Other: Blood tests
Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
Other: Stool sample collections (optional)
Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
Other: Hypoglycemia journal
During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
Other: Ketone journal
During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
Other: Adherence to the diet (Keenoa)
During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
|
| Active Comparator: Low-CHO Diet 30% of energy from CHO, 15% proteins and 55% lipids |
Other: Insulin treatment optimization with participant's usual diet
Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
Device: Abbott's FreeStyle Libre
During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
Other: Three-day food journal
Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
Other: Medical visit
During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
Other: Blood pressure measurements
Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
Other: Anthropometric parameters measurements
Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
Other: Indirect calorimetry test
Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
Other: Well-being questionnaire
Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
Other: Diet appreciation questionnaire
Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
Device: Pedometer (PiezoRxD)
Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
Other: Hepatic imaging (MRI)
Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
Other: Glucagon efficiency test
The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
Other: Body composition : Dual Energy X-ray absorptiometry (DEXA)
Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
Other: Blood tests
Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
Other: Stool sample collections (optional)
Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
Other: Hypoglycemia journal
During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
Other: Ketone journal
During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
Other: Adherence to the diet (Keenoa)
During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
|
| Placebo Comparator: Control Diet 50% of energy from CHO, 15% proteins and 35% lipids |
Other: Insulin treatment optimization with participant's usual diet
Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
Device: Abbott's FreeStyle Libre
During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
Other: Three-day food journal
Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
Other: Medical visit
During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
Other: Blood pressure measurements
Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
Other: Anthropometric parameters measurements
Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
Other: Indirect calorimetry test
Both resting metabolic rate and respiratory quotient will be measured after a 10-hour fast by indirect calorimetry. The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
Other: Well-being questionnaire
Participants will be asked to complete a well-being questionnaire (nausea, fatigue, etc) during visits 2, 3 and 4.
Other: Diet appreciation questionnaire
Participants will be asked to complete a diet appreciation (appetite, fullness, etc) questionnaire during visits 3 and 4.
Device: Pedometer (PiezoRxD)
Participants will be asked to wear a pedometer (PiezoRxD) that will record their steps every day during the whole trial. Also, they will have to install Piezo: Achieve the Guidelines!, a free mobile application, on their smartphone or tablet. It will connect to their pedometer via bluetooth and will help the research assistant track their data remotely
Other: Hepatic imaging (MRI)
Imaging of participants' liver will be done by MRI at the Centre Hospitalier de l'Université de Montréal (CHUM). The test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
Other: Glucagon efficiency test
The glucagon efficiency test will be done twice, before (visit 2) and after (visit 4) the intervention phase. A subcutaneous insulin injection based on individual insulin correction factor will be given to induce hypoglycemia down to 3 mmol/L (based on plasma glucose). A subcutaneous injection of 300 µg of glucagon will be administered.
Other: Body composition : Dual Energy X-ray absorptiometry (DEXA)
Lean body mass and fat mass will be measured by Dual Energy X-ray absorptiometry (DEXA). The DEXA test will be done twice, before (visit 2) and after (visit 4) the intervention phase.
Other: Blood tests
Blood tests will be done to assess participants' diabetes control as well as to assess other biochemical markers (blood lipids as well as markers of inflammation and liver function). Blood will be collected and analyzed during all visits (visits 1 to 4).
Other: Stool sample collections (optional)
Participants will be asked to collect and immediately freeze their stool sample until it is given to the study team (for intestinal microbiota composition analysis). This will be done three times during the study, during phase 1, between week 1 and 6 of phase 2 and between week 6 and 12 of phase 2.
Other: Hypoglycemia journal
During the whole trial, participants will be asked to keep a log of their hypoglycemia episodes, which are defined by the need to consume CHO. They will be asked to note the time, symptoms (including time taken for disappearance after treatment), capillary glucose measurement and the amount of CHO consumed.
Other: Ketone journal
During the intervention phase, participants will be asked to measure their ß-hydroxybutarate level (mmol/L) with their Abbott's Freestyle-Libre scanner at least twice per week before breakfast. Participants will be asked to check their ketone bodies for sensor or capillary glucose levels exceeding 15 mmol/l, when their sensor indicates high without a specific glucose value and when they have symptoms of ketoacidosis (regardless of glucose reading).
Other: Adherence to the diet (Keenoa)
During the whole dietary intervention phase (phase 2), participants will confirm that they have followed their menus by taking before and after pictures of their meals every day and indicating the percentage of their meal consumed (25-50-75-100%) via the Keenoa mobile application.
|
Outcome Measures
Primary Outcome Measures
- Percentage of time-in-target (range of 4-10 mmol/L) [From enrollment to end of study, total of 14 weeks]
Using continuous glucose monitoring (FreeStyle Libre)
Secondary Outcome Measures
- Time to resolve an induced hypoglycemia (>4 mmol/L) [After administration of subcutaneous insulin; At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 5 hours]
Glucagon efficiency test
- Peak plasma glucose level two hours after glucagon administration [After administration of glucagon; At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 5 hours]
Glucagon efficiency test
- Glycated hemoglobin (HbA1c) [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Average glycemic control
- Fructosamine [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Average glycemic control
- Fasting blood glucose [From beginning (week 3) to end (week 14) of diet intervention]
Blood glucose before meals
- Post-prandial blood glucose [From beginning (week 3) to end (week 14) of diet intervention]
Blood glucose after meals
- Coefficient of glucose variation (%) [From enrollment to end of study, total of 14 weeks]
Using continuous glucose monitoring (FreeStyle Libre)
- Insulin daily dose [From enrollment to end of study, total of 14 weeks]
Using continuous glucose monitoring (FreeStyle Libre) or their insulin pump
- Basal insulin doses [From enrollment to end of study, total of 14 weeks]
Using continuous glucose monitoring (FreeStyle Libre) or their insulin pump
- Insulin-to-CHO ratio [From enrollment to end of study, total of 14 weeks]
Using continuous glucose monitoring (FreeStyle Libre) or their insulin pump
- Percentage of time spent in hypoglycemia ranges < 4 mmol/L [From enrollment to end of study, total of 14 weeks]
Using continuous glucose monitoring (FreeStyle Libre)
- Percentage of time spent in significant hypoglycemia ranges < 3 mmol/L [From enrollment to end of study, total of 14 weeks]
Using continuous glucose monitoring (FreeStyle Libre)
- Weight (kg) [At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Weight and height will be combined to report BMI (kg/m^2)
- Height (cm) [At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Weight and height will be combined to report BMI (kg/m^2)
- Waist circumference (cm) [At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Calculated using the average of 3 measures
- Total cholesterol [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Blood lipid profiles
- HDL-cholesterol [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Blood lipid profiles
- LDL-cholesterol [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Blood lipid profiles
- Triglycerides [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Blood lipid profiles
- Apo-B [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Blood lipid profiles
- Apo-A1 [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Blood lipid profiles
- Total lean mass (kg) [During DEXA-scan : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 15 minutes]
Measured by DEXA (Dual-Energy X-ray Absorptiometry)
- Total lean mass (%) [During DEXA-scan : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 15 minutes]
Measured by DEXA (Dual-Energy X-ray Absorptiometry)
- Truncal lean mass (kg) [During DEXA-scan : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 15 minutes]
Measured by DEXA (Dual-Energy X-ray Absorptiometry)
- Truncal lean mass (%) [During DEXA-scan : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 15 minutes]
Measured by DEXA (Dual-Energy X-ray Absorptiometry)
- Total fat mass (kg) [During DEXA-scan : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 15 minutes]
Measured by DEXA (Dual-Energy X-ray Absorptiometry)
- Total fat mass (%) [During DEXA-scan : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 15 minutes]
Measured by DEXA (Dual-Energy X-ray Absorptiometry)
- Truncal fat mass (kg) [During DEXA-scan : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 15 minutes]
Measured by DEXA (Dual-Energy X-ray Absorptiometry)
- Truncal fat mass (%) [During DEXA-scan : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 15 minutes]
Measured by DEXA (Dual-Energy X-ray Absorptiometry)
- Systolic blood pressure (mmHg) [At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Calculated using the average of 3 measures
- Diastolic blood pressure (mmHg) [At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Calculated using the average of 3 measures
- Aminotransferases [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Liver function
- Alkaline phosphatase [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Liver function
- Gamma-glutamyl transpeptidase [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Liver function
- Bilirubin [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Liver function
- Albumin [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Liver function
- High sensitivity CRP [During blood test : At baseline (day 1), before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Liver function
- Resting metabolic rate (kcal/day) [During indirect calorimetry test : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 30 minutes]
Measured by indirect calorimetry
- Respiratory quotient [During indirect calorimetry test : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 30 minutes]
Measured by indirect calorimetry
- Liver proton density fat fraction [During MRI : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 30 minutes]
Hepatic fat imagery measured by MRI
- Mean liver PDFF [During MRI : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 30 minutes]
Hepatic fat imagery measured by MRI
- Total liver volume [During MRI : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 30 minutes]
Hepatic fat imagery measured by MRI
- Total liver fat index [During MRI : At beginning (week 3) and end (week 14) of the diet intervention, each test lasts approximately 30 minutes]
Hepatic fat imagery measured by MRI
- Well-being score [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
The World Health Organisation- Five Well-Being Index (WHO-5) : I have felt cheerful in good spirits, I have felt calm and relaxed, I have felt active and vigorous, I woke up feeling fresh and rested, My daily life has been filled with things that interest me. The raw score is calculated by totaling the figures of the five answers (0 = At no time to 5 = All of the time). The raw score ranges from 0 to 25, 0 representing worst possible and 25 representing best possible quality of life.
- Visual Analog Score for fatigue (none to intolerable) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Corresponding scores of questionnaire used to assess different quality of life aspects.
- Visual Analog Score for nausea (none to intolerable) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Corresponding scores of questionnaire used to assess different quality of life aspects.
- Visual Analog Score for abdominal cramp/pain (none to intolerable) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Corresponding scores of questionnaire used to assess different quality of life aspects.
- Visual Analog Score for headache (none to intolerable) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Corresponding scores of questionnaire used to assess different quality of life aspects.
- Visual Analog Score for hunger (none to intolerable) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Corresponding scores of questionnaire used to assess different quality of life aspects.
- Visual Analog Score for diet satisfaction (not appreciated to very appreciated) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Corresponding scores of questionnaire for diet appreciation.
- Visual Analog Score for difficulty to follow the diet (no difficulty to extreme difficulty) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Corresponding scores of questionnaire for diet appreciation.
- Visual Analog Score for difficulty for meal preparation (no difficulty to extreme difficulty) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Corresponding scores of questionnaire for diet appreciation.
- Steps/day (physical activity) [From enrollment to end of study, total of 14 weeks]
Recorded with a pedometer (PiezoRxD) and mobile application
- Number hypoglycemia episodes [From enrollment to end of study, total of 14 weeks]
Recorded by participants on hypoglycemia journal
- Severity of hypoglycemia episodes (mild or severe) [From enrollment to end of study, total of 14 weeks]
Recorded by participants on hypoglycemia journal
- Capillary ketone body levels [From beginning (week 3) to end (week 14) of diet intervention]
ß-hydroxybutarate level (mmol/L) measured using ketometer integrated in Abbott's Freestyle-Libre scanner
- Alpha diversity (optional) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Intestinal microbiota composition (optional)
- Beta diversity (optional) [Before diet intervention (week 3), halfway the diet intervention (week 8) and at the end of the diet intervention (week 14)]
Intestinal microbiota composition (optional)
- Daily caloric intake (kcal/day) [Three days during the first 2 weeks (3-day food journal) and from beginning (week 3) to end (week 14) of diet intervention]
Using Keenoa's mobile application
- Lipids composition [Three days during the first 2 weeks (3-day food journal) and from beginning (week 3) to end (week 14) of diet intervention]
Using Keenoa's mobile application. Grams will be converted into percentage of energy.
- Carbohydrates composition [Three days during the first 2 weeks (3-day food journal) and from beginning (week 3) to end (week 14) of diet intervention]
Using Keenoa's mobile application. Grams will be converted into percentage of energy.
- Proteins composition [Three days during the first 2 weeks (3-day food journal) and from beginning (week 3) to end (week 14) of diet intervention]
Using Keenoa's mobile application. Grams will be converted into percentage of energy.
- Self-reported symptoms [From enrollment to end of study, total of 14 weeks]
Descriptive symptoms reported by participants during follow-ups
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Men and women > 18 years old
-
Duration of T1D > 12 months
-
On intensive insulin therapy
-
Own a smartphone or tablet to use two mobile applications for nutritional and physical activity tracking: Keenoa and Piezo: Achieve the Guidelines!
Exclusion Criteria:
-
Already following a low-CHO diet (<30% CHO)
-
Type 2 diabetes or other form of diabetes
-
Known gastroparesis (clinical diagnosis)
-
Advanced kidney disease (eGFR < 50 mL/min)
-
Known significant liver disease (e.g. cirrhosis, active hepatitis, liver transplantation)
-
Recent (<6 months) major cardiovascular event (e.g. myocardial infarction, cerebrovascular accident, major revascularization, etc.)
-
Pregnancy (ongoing or planned in the next 6 months)
-
Breastfeeding (ongoing)
-
Recent severe hypoglycemia episodes (BG <2.8 mmol/L or assistance from a third party) or ketoacidosis (<6 weeks)
-
Claustrophobia or presence of metal devices/implants in the body
-
Recent (<6 weeks) or planned (next 6 months) modification in insulin treatment
-
Recent (<6 weeks) or planned (next 6 months) modification in cardiometabolic drugs for blood pressure and/or lipids. These drugs must remain stable all along the trial
-
Off label adjunct therapy with SGLT-2 inhibitors (Forxiga®, Invokana® or Jardiance®)
-
Recent (<6 weeks) or planned (next 6 months) modification of adjunct therapy (Metformin, Glumetza®, Victoza®, Trulicity® and Ozempic®)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Institut de recherches cliniques de Montréal | Montréal | Quebec | Canada | H2W 1R7 |
Sponsors and Collaborators
- Institut de Recherches Cliniques de Montreal
- McGill University
Investigators
- Principal Investigator: Rémi Rabasa-Lhoret, Institut de recherches cliniques de Montréal
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CUT-1